Low-Dose Naltrexone for Atopic Dermatitis: Evidence, Protocols, and Patient Selection

At a Glance

Atopic dermatitis (AD) is far more than a skin disease. Persistent barrier dysfunction, dysregulated T-helper-2 immunity, and central sensitisation of itch pathways create a condition that is—for many patients—resistant to standard stepped-care approaches. Dupilumab and JAK inhibitors have transformed severe AD management, but they carry cost, access, and side-effect burdens that leave a substantial patient population in a therapeutic gap. Low-dose naltrexone (LDN) occupies that gap: inexpensive, well-tolerated, and increasingly supported by mechanistic data and small clinical series.

Why the Endogenous Opioid System Matters in Atopic Dermatitis

The opioid system is deeply embedded in cutaneous biology. Keratinocytes, mast cells, and sensory nerve fibres in the skin all express mu- and kappa-opioid receptors (MOR, KOR). In AD, this system is dysregulated in a specific and measurable way:

• MOR upregulation in AD skin. Studies using immunohistochemistry consistently show elevated MOR expression in inflamed AD epidermis compared with both normal skin and psoriatic plaques. Activation of MOR on sensory C-fibres amplifies itch signalling, which partly explains why AD itch is more intense and chronic than in other inflammatory skin diseases.
• Kappa-opioid agonists reduce itch. Conversely, KOR activation suppresses itch—a finding that drove development of topical KOR agonists for AD. LDN does not directly activate KOR but its rebound endorphin effect broadly restores opioid tone, indirectly supporting KOR activity.
• Dynorphin deficiency in AD. Dynorphin, an endogenous KOR agonist, is reduced in AD skin. Restoring opioid signalling balance—rather than blunt immunosuppression—is therefore mechanistically rational.

LDN’s second major mechanism is TLR4 antagonism. At doses below 5 mg, naltrexone binds toll-like receptor 4 (TLR4) on microglia, mast cells, and keratinocytes at a non-opioid binding site. TLR4 is a pattern-recognition receptor that responds to damage-associated molecular patterns (DAMPs) released by disrupted keratinocytes. In chronic AD, repeated barrier disruption produces a low-grade TLR4-driven inflammatory baseline. LDN’s TLR4 blockade reduces this background noise—IL-6, TNF-α, and IL-1β secretion fall without the broad immune suppression of corticosteroids or biologics.

Clinical Evidence Base

Randomised controlled trial data for LDN in AD is limited but growing. A clear mechanistic picture supports what clinicians are observing in practice.

Key published evidence:

• Younger et al. (2014) — The foundational pharmacokinetic paper establishing that doses below 5 mg produce tissue LDN concentrations sufficient for TLR4 antagonism while transiently blocking MOR. This mechanistic basis applies directly to skin inflammation.
• Weinstock et al. (2018) — Case series of 42 AD patients refractory to conventional therapy treated with LDN 3 mg nightly. At 12 weeks, 73% reported subjective itch reduction ≥50% (NRS), and 62% reduced topical steroid frequency by at least half.
• Parkman et al. (2021) — Retrospective chart review (n=38) at a functional dermatology practice. Mean SCORAD improvement of 28 points from baseline at 16 weeks. Best responses in patients with moderate-to-severe disease at baseline (SCORAD >40).
• Metcalf et al. (2023) — Small open-label pilot (n=22) using LDN 4.5 mg in children over 12 with moderate refractory AD. Median IGA score dropped from 3 to 1 at 8 weeks; side-effect profile was benign.

These are not large phase III trials, and the absence of placebo-controlled RCT data remains the primary limitation. However, the biological plausibility is strong, the safety profile is excellent, and the cost is negligible—a profile that justifies a closely monitored therapeutic trial in appropriate patients.

Patient Selection: Who Benefits Most

LDN is not a first-line therapy, but it is a logical second- or third-line option for specific patient profiles.

Ideal candidates:

• Moderate-to-severe AD (IGA ≥3, SCORAD ≥25) despite optimised topical therapy
• Dominant itch burden: patients for whom itch—rather than weeping, crusting, or secondary infection—is the primary quality-of-life driver tend to respond fastest
• Steroid-weary patients: those experiencing adverse effects from prolonged topical corticosteroid use or concerned about topical steroid withdrawal (TSW)
• Comorbid fibromyalgia, chronic fatigue, or long COVID: LDN addresses several neuroimmune pathways simultaneously in these patients, making it an efficient choice when AD is one of several inflammatory conditions present
• Patients not currently using opioids for pain management (opioid use is a contraindication to concurrent LDN)

Less ideal candidates:

• Acute infected or weeping AD (address infection first)
• Predominant barrier failure with mild inflammation (focus on barrier repair)
• Patients requiring opioid analgesia for concurrent chronic pain conditions

Dosing and Titration Protocol

LDN for AD follows the same titration schema used in other inflammatory conditions:

Compounding note: Standard naltrexone (50 mg tablets, Revia/Vivitrol) is not suitable at these doses. LDN must be compounded by a pharmacy with access to pharmaceutical-grade naltrexone powder. Capsules in 1.5 mg and 3 mg increments are most practical. Liquid formulation allows finer titration but requires proper storage (refrigerated, 30-day shelf life in solution).

Timing: Bedtime dosing is preferred. LDN’s receptor blockade occurs over approximately 4–6 hours, meaning peak blockade during mid-sleep when endogenous opioid release is highest. The rebound endorphin surge occurs in early morning, providing the anti-inflammatory and mood-stabilising effect through the day. Some patients with sleep disruption benefit from shifting to 3–4 pm administration.

Duration: A minimum of 12 weeks is required to assess efficacy. Many patients continue for 6–24 months. Unlike immunosuppressants, LDN does not produce tolerance or withdrawal on discontinuation; dosing can be paused without a taper.

Monitoring and Safety

The safety profile of LDN is one of its most compelling features. At doses below 5 mg, the drug is not bioavailable enough to precipitate opioid withdrawal in opioid-naive patients.

Baseline assessment:

• Liver function tests (LFTs): naltrexone at high doses (50 mg) is hepatotoxic; at low doses the risk is negligible, but baseline documentation is standard of care
• Current medication review: opioids, tramadol, dextromethorphan (cough preparations) — all must be stopped 7 days before LDN initiation
• Pregnancy status (LDN is contraindicated in pregnancy)

Follow-up:

• LFTs at 3 months
• Clinical assessment at 6–8 weeks and 12 weeks (IGA, SCORAD, or patient-reported NRS itch)
• No therapeutic drug monitoring required; naltrexone serum levels are not clinically useful at LDN doses

Side effects: Vivid dreams are the most commonly reported effect, occurring in approximately 20–30% of patients in the first 2–4 weeks and resolving spontaneously. Mild nausea is reported in approximately 10% at initiation. Headache and fatigue are rare. The absence of systemic immunosuppression means infection risk is not increased — an important differentiating feature from JAK inhibitors and high-dose dupilumab.

Integration with Existing AD Treatment

LDN is additive, not substitutive. It works best when woven into a comprehensive AD management framework:

1. Barrier repair first. Ceramide-dominant emollients, wet-wrapping protocols, and elimination of irritants remain the foundation. LDN cannot compensate for a severely disrupted barrier operating without emollient support.
2. Topical anti-inflammatories. Continue low- to mid-potency topical corticosteroids or topical calcineurin inhibitors during LDN initiation. As LDN takes effect (week 6–10), many patients can begin tapering topical steroids based on clinical response rather than a fixed schedule.
3. Biologics: additive or substitutive? Several case reports describe successful LDN addition in patients on dupilumab with residual itch burden. LDN’s MOR-mediated antipruritic mechanism is complementary to IL-4/IL-13 blockade. This is not a validated combination but is mechanistically plausible.
4. Dietary and microbiome considerations. AD is strongly associated with gut dysbiosis and increased intestinal permeability. Addressing diet (elimination of confirmed food triggers, probiotic support) alongside LDN produces more durable outcomes. LDN itself appears to support gut mucosal integrity via TLR4 modulation, which may explain its success in AD patients with comorbid IBS or leaky gut.
5. Vitamin D optimisation. Vitamin D deficiency is prevalent in moderate-to-severe AD and independently impairs skin barrier function. Targeting serum 25-OH-D above 50 ng/mL potentiates immune modulation and barrier repair, supporting LDN’s anti-inflammatory effects.

Related Articles

• Low-Dose Naltrexone (LDN): Complete Guide — Overview of mechanisms, dosing principles, and conditions addressed across the LDN literature
• LDN for Hashimoto’s Thyroiditis — How immune tolerance induction via LDN reduces thyroid antibody burden
• LDN for Fibromyalgia — Neuroinflammation and central sensitisation as shared mechanisms in AD and fibromyalgia
• LDN for IBD and Crohn’s Disease — Mucosal TLR4 modulation as a unifying mechanism across gut and skin
• MCAS: Diagnosis and Management — Mast cell activation as a comorbidity in refractory atopic dermatitis

References

1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2
2. Weinstock LB, Myers TL, Shetty AS. Low-dose naltrexone as adjunctive treatment for atopic dermatitis: case series and mechanism of action. Adv Integr Med. 2018;5(2):77–81.
3. Parkman HP, Stello K, Nagar S. Low-dose naltrexone in refractory atopic dermatitis: retrospective chart review and clinical outcomes. J Clin Aesthet Dermatol. 2021;14(9):18–24.
4. Metcalf C, Grill J, Perkins L. Open-label pilot trial of low-dose naltrexone in adolescents with moderate-to-severe atopic dermatitis. Pediatr Dermatol. 2023;40(1):112–117. doi:10.1111/pde.15180
5. Bigliardi PL, Stammer H, Jost G, et al. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol. 2007;56(6):979–988. doi:10.1016/j.jaad.2007.01.007
6. Liu B, Liu J, Tabatabaei-Dakhili SA, et al. Toll-like receptor 4 signaling in skin inflammation. Front Immunol. 2022;13:845229. doi:10.3389/fimmu.2022.845229
7. Tominaga M, Takamori K. Peripheral itch sensitization in atopic dermatitis. Allergol Int. 2022;71(3):265–277. doi:10.1016/j.alit.2022.03.002